Clinical Trial Results:
A Randomized, International, Double-Blinded (With In-House Blinding), Controlled
With GARDASIL™, Tolerability, Immunogenicity, and Efficacy Study of a Second
Generation Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine
Administered to 16- to 26-Year-Old Women
Summary
|
|
EudraCT number |
2006-004933-14 |
Trial protocol |
DK |
Global completion date |
22 Feb 2007
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
08 Jun 2019
|
First version publication date |
08 Jun 2019
|
Other versions |
|
Summary report(s) |
Cancelled/ Withdrawn Memo |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.